Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML

Activating FLT3 internal tandem duplication (FLT3-ITD) mutations in acute myeloid leukemia (AML) associate with inferior outcomes. We determined that pacritinib, a JAK2/FLT3 inhibitor, has in vitro activity against FLT3-ITD and tyrosine kinase domain (TKD) mutations. Therefore, we conducted a phase...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Invest New Drugs
Главные авторы: Jeon, Jae Yoon, Zhao, Qiuhong, Buelow, Daelynn R., Phelps, Mitch, Walker, Alison R., Mims, Alice S., Vasu, Sumithira, Behbehani, Gregory, Blachly, James, Blum, William, Klisovic, Rebecca B., Byrd, John C., Garzon, Ramiro, Baker, Sharyn D., Bhatnagar, Bhavana
Формат: Artigo
Язык:Inglês
Опубликовано: 2019
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6858927/
https://ncbi.nlm.nih.gov/pubmed/31102119
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-019-00786-4
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы